Single Regulator (SIA-31-C18)
Peptide Receptor Modulator Research Series – Single, Dual, and Triple Agonist Investigational Compounds.
| Product Specifications | |
|---|---|
| CAS Number | 910463-68-2 |
| Molecular Formula | C187H291N45O59 |
| Molecular Weight (g/mol) | 4113.58 |
| Amino Acid Count | 31 |
| Amino Acid Sequence | H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(Nε-(γ-Glu-(2x AEEA)-octadecanedioyl))-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH |
| Purity | ≥99% by HPLC | COA available |
| Physical Form | Lyophilized powder |
| Solubility | Soluble in bacteriostatic water; consult COA for specific solvent recommendations |
| Storage Conditions | Store at -20°C; protect from light and moisture; reconstitute with bacteriostatic water |
For Research Use Only. Not for use in diagnostic, therapeutic, or human or animal in-vivo procedures.
This product is sold exclusively for in-vitro laboratory research use. It is not a drug, dietary supplement, food, or cosmetic and has not been approved by the U.S. Food and Drug Administration for any use. This product is not intended to diagnose, treat, cure, mitigate, or prevent any disease. Not for human or animal consumption.
Published Literature
| # | Reference | Link |
|---|---|---|
| [01] | Wilding J.P.H., Batterham R.L., Calanna S., et al. Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med. 2021;384(11):989–1002. (New England Journal of Medicine) | View Publication |
| [02] | Lincoff A.M., Brown-Frandsen K., Colhoun H.M., et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N. Engl. J. Med. 2023;389(24):2221–2232. (PubMed) | View Publication |
| [03] | Perkovic V., Tuttle K.R., Rossing P., et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N. Engl. J. Med. 2024;391(2):109–121. (Unbound Medicine) | View Publication |
| [04] | Marso S.P., Daniels G.H., Brown-Frandsen K., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 2016;375:311–322. (New England Journal of Medicine) | View Publication |
| [05] | Gerstein H.C., Colhoun H.M., Dagenais G.R., et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes: REWIND trial. Lancet. 2019;394(10193):121–130. (The Lancet) | View Publication |
| [06] | Sattar N., Lee M.M.Y., Kristensen S.L., et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2021;9:653–662. (The Lancet) | View Publication |
| [07] | He L., Wang J., Ping F., et al. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern. Med. 2022;182(5):513–519. (PubMed) | View Publication |
Receptor Binding Profile
| Compound | Primary Receptor Target | Binding / Activity Profile | Reported Potency / Affinity | Functional Effect |
|---|---|---|---|---|
| Semaglutide | GLP-1 receptor (GLP-1R) | Selective GLP-1 receptor agonist; binds to and activates the same receptor targeted by native GLP-1 | IC50: 0.38 nM in a human GLP-1 receptor radioligand displacement assay; EC50: 0.01 nM in human GLP-1R activation assay | Activates GLP-1R signaling, which is associated with glucose-dependent insulin secretion, reduced glucagon secretion, delayed gastric emptying, and appetite regulation in clinical pharmacology sources (IUPHAR/BPS Guide to Pharmacology) |